HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Another example is the HDAC inhibitor vorinostat, which has a favorable safety and tolerability profile when used in monotherapy or in conjunction with other therapies for the treatment of cutaneous T-cell lymphoma (CTCL) [68].